Thermo Fisher Scientific Q1 2024 Adj EPS $5.11 Beats $4.71 Estimate, Sales $10.340B Beat $10.170B Estimate
Portfolio Pulse from Benzinga Newsdesk
Thermo Fisher Scientific (TMO) reported Q1 2024 adjusted EPS of $5.11, surpassing the $4.71 estimate, and sales of $10.340B, exceeding the $10.170B estimate. This represents a 1.59% increase in EPS and a 3.45% decrease in sales from the same period last year.

April 24, 2024 | 10:00 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Thermo Fisher Scientific reported a strong Q1 2024 with adjusted EPS of $5.11 and sales of $10.340B, both exceeding analyst estimates.
Beating both EPS and sales estimates indicates strong financial performance and operational efficiency. This positive earnings report is likely to instill investor confidence, potentially leading to a short-term uptick in TMO's stock price. The increase in EPS compared to the same period last year, despite a slight decrease in sales, highlights effective cost management and profitability, further supporting a positive outlook.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100